Immune Response Against Viral Pathogens
Cross-reactivity
Antigens Involved in Adaptive Immunity
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 27, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Ritu R Bradley1, Lori F Maxfield, Diana M Lynch
1Division of Vaccine Research, Beth Israel Deaconess Medical Center, and Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
Adenovirus serotype 5 (Ad5) vector immunogenicity is reduced by neutralizing antibodies (NAbs). Replacing all hexon hypervariable regions (HVRs) is necessary to evade pre-existing Ad5 immunity, crucial for vaccine and gene therapy vector development.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: